Citation Impact
Citing Papers
Rab27a Supports Exosome-Dependent and -Independent Mechanisms That Modify the Tumor Microenvironment and Can Promote Tumor Progression
2012
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
2009 StandoutNobel
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
2011
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
2004
Hallmarks of Cancer: The Next Generation
2011 Standout
Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m 6 A-demethylation of NANOG mRNA
2016 StandoutNobel
Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma
2001
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
2015
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
2019
Cardiotoxic effects of anthracycline–taxane combinations
2003
Breast cancer
2016 Standout
Exosomes: immune properties and potential clinical implementations
2010
Estimated number of prevalent cases of metastatic bone disease in the US adult population
2012
Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments
2011
Exosomes
2013
Tumor exosomes block dendritic cells maturation to decrease the T cell immune response
2018
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
Non-specific low back pain
2016 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
The evolution of the cancer niche during multistage carcinogenesis
2013
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
A Novel Nanoparticle Drug Delivery System: The Anti-inflammatory Activity of Curcumin Is Enhanced When Encapsulated in Exosomes
2010 Standout
Doxorubicin‐paclitaxel
2002
Individual patient data analysis to assess modifications to the RECIST criteria
2008
Membrane vesicles as conveyors of immune responses
2009 Standout
Shedding light on the cell biology of extracellular vesicles
2018 Standout
Diagnostic and therapeutic management of cancer of an unknown primary
2003
Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts
1997
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts
2011
Chemosensitisation of malignant melanoma by BCL2 antisense therapy
2000
Role of anthracyclines in the era of targeted therapy
2007
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Retreatment of patients with the same chemotherapy: Implications for clinical mechanisms of drug resistance
2001
Apoptosis
2002 Standout
EMT: 2016
2016 Standout
Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer
2001
Management of Metastatic Melanoma 2005
2006
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Communication by Extracellular Vesicles: Where We Are and Where We Need to Go
2016 Standout
Regulation of immune responses by extracellular vesicles
2014 Standout
Prevalence and outcomes of anemia in cancer: a systematic review of the literature
2004
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I–II study
2000
Phase I Study of Paclitaxel (Taxol) and Pegylated Liposomal Doxorubicin (Caelyx) Administered Every 2 Weeks in Patients with Advanced Solid Tumors
2002
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
Interleukin-2: Clinical applications
2002
MicroRNA expression profiles classify human cancers
2005 StandoutNatureNobel
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Extracellular vesicles: biology and emerging therapeutic opportunities
2013 Standout
Preservation of Fertility in Patients with Cancer
2009 Standout
Stem cell-derived polarized hepatocytes
2020 StandoutNobel
Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer
2010
Update on tubulin-binding agents
2005
Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
1994
Phase I Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Advanced Breast Cancer
2001
Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications
2015 StandoutNobel
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Extracellular vesicles: Exosomes, microvesicles, and friends
2013 Standout
Exosomes Packaging APOBEC3G Confer Human Immunodeficiency Virus Resistance to Recipient Cells
2008
Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes
2016 Standout
Antitumor activity of imidazole derivatives: dacarbazine and the new alkylating agent imidazene (Review)
2010
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
2008
Azole-Based Energetic Salts
2011 Standout
Nonviral Vectors for Gene Delivery
2008 Standout
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
2012
Cytokine Storm
2020 Standout
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Going live with tumor exosomes and microvesicles
2017
Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease.
1999
The biology and function of exosomes in cancer
2016
Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
2010
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
1997
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
1999 Standout
Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group
2006
Dendritic Cell–Derived Exosomes as Immunotherapies in the Fight against Cancer
2014
Chimeric Antigen Receptor Therapy
2018 Standout
Extending Survival with Chemotherapy in Metastatic Breast Cancer
2005
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206
2005
Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study
2015
Exosomes and Cancer: A Newly Described Pathway of Immune Suppression
2011
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
2016
Inflammation and metabolism in tissue repair and regeneration
2017 StandoutScience
Alternatively activated macrophages determine repair of the infarcted adult murine heart
2016
Adipose Tissue Exosome-Like Vesicles Mediate Activation of Macrophage-Induced Insulin Resistance
2009
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p
2015
Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities
2001
Works of Carla I. Falkson being referenced
Fludarabine: A Phase II Trial in Patients with Previously Treated Low-Grade Lymphoma
1996
A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer
1996
Prognostic Factors in Metastatic Malignant Melanoma
1997
Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999–2006
2011
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
1998
Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: an Eastern Cooperative Oncology Group study.
1994
Pilot Trial of Preoperative (Neoadjuvant) Letrozole in Combination With Bevacizumab in Postmenopausal Women With Newly Diagnosed Estrogen Receptor— or Progesterone Receptor—Positive Breast Cancer
2010
Hepatocellular carcinoma
1998
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial
2012
Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.
1991
A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates
2004
A Randomized Trial of Mitomycin-C (M) Versus Mitomycin-C Plus High-Dose Medroxyprogesterone Acetate (MMPA) in the Treatment of Patients with Advanced Breast Cancer
1993
Phase II Study of Interleukin-4 in Indolent B-cell Non-Hodgkin Lymphoma and B-cell Chronic Lymphocytic Leukemia: A Study of the Eastern Cooperative Oncology Group (E5Y92)
2010
Recombinant Human Erythropoietin in the Treatment of Cancer-Related Anaemia
1994
Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.
1991
Mitomycin C, Epirubicin and Cisplatin versus Mitomycin C Alone as Therapy for Carcinoma of Unknown Primary Origin
1998
Phase II Trial of Doxorubicin and Paclitaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: An Eastern Cooperative Oncology Group Study
1999
Phase II Trial of Doxorubicin and Docetaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: Eastern Cooperative Oncology Group Study E1196
2000
Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial
2003
Tumor Exosomes Inhibit Differentiation of Bone Marrow Dendritic Cells
2007